Search

10X Genomics Inc (Class A)

Open

BrancheGesundheitswesen

49.74 9.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

44.21

Max

48.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.8M

-13M

Verkäufe

-15M

151M

EPS

0.07

Gewinnspanne

-8.93

Angestellte

1,178

EBITDA

19M

-937K

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-5.7% downside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.2B

6B

Vorheriger Eröffnungskurs

40.13

Vorheriger Schlusskurs

49.74

Nachrichtenstimmung

By Acuity

100%

0%

329 / 340 Ranking in Healthcare

10X Genomics Inc (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2026, 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5. Aug. 2026, 19:26 UTC

Correlated Moves
News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3. Aug. 2026, 19:36 UTC

Correlated Moves
Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31. Juli 2026, 19:36 UTC

Correlated Moves
Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30. Juli 2026, 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29. Juli 2026, 19:27 UTC

Macro Event
News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28. Juli 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27. Juli 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24. Juli 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23. Juli 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22. Juli 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21. Juli 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20. Juli 2026, 19:16 UTC

News
Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Peer-Vergleich

Kursveränderung

10X Genomics Inc (Class A) Prognose

Kursziel

By TipRanks

-5.7% Nachteil

12-Monats-Prognose

Durchschnitt 43 USD  -5.7%

Hoch 53 USD

Tief 23 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für 10X Genomics Inc (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

5

Buy

8

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat